Gyroscope Therapeutics Holdings plc announced that it will receive up to £44.5 million in an equity round of funding from new investor, Sanofi Ventures on November 8, 2021. The investor will invest £29.666666 million initially, at a premium to company's prior Series C financing, and the remaining £14.833333 million will be invested contingent on a future qualifying investment round and subject to the satisfaction of certain closing conditions. As a part of the transaction, a Sanofi R&D executive will join the company's Clinical Advisory Board.
Gyroscope Therapeutics Holdings plc
Equities
VISN
US40382N1037
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+46.19% | 55.7B | |
-6.14% | 39.57B | |
+40.68% | 39.91B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
-0.35% | 12.12B | |
+24.18% | 12.12B | |
+28.38% | 12.17B |